These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772 [TBL] [Abstract][Full Text] [Related]
9. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Vincent FB; Morand EF; Murphy K; Mackay F; Mariette X; Marcelli C Ann Rheum Dis; 2013 Feb; 72(2):165-78. PubMed ID: 23178294 [TBL] [Abstract][Full Text] [Related]
11. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871 [TBL] [Abstract][Full Text] [Related]
12. A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease. Barrau M; Duprat M; Veyrard P; Tournier Q; Williet N; Marc Phelip J; Waeckel L; Cheifetz AS; Papamichael K; Roblin X; Paul S J Crohns Colitis; 2023 Apr; 17(4):633-643. PubMed ID: 36301958 [TBL] [Abstract][Full Text] [Related]
13. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879 [TBL] [Abstract][Full Text] [Related]
14. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. Thomas SS; Borazan N; Barroso N; Duan L; Taroumian S; Kretzmann B; Bardales R; Elashoff D; Vangala S; Furst DE BioDrugs; 2015 Aug; 29(4):241-58. PubMed ID: 26280210 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. Strand V; Gonçalves J; Hickling TP; Jones HE; Marshall L; Isaacs JD BioDrugs; 2020 Feb; 34(1):27-37. PubMed ID: 31721107 [TBL] [Abstract][Full Text] [Related]
16. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629 [TBL] [Abstract][Full Text] [Related]
18. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998 [TBL] [Abstract][Full Text] [Related]
19. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892 [No Abstract] [Full Text] [Related]
20. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]